financetom
Business
financetom
/
Business
/
Granite Construction Q2 revenue misses expectations
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Granite Construction Q2 revenue misses expectations
Aug 7, 2025 4:09 AM

Overview

* Granite Q2 revenue rises 4% yr/yr, misses analyst expectations, per LSEG data

* Adjusted EPS of $1.93 for Q2 beats consensus, per LSEG data

* The infrastructure contractor andconstructionmaterials producer raises 2025 guidance post acquisitions

Outlook

* Company raises 2025 revenue guidance to $4.35 bln-$4.55 bln

* Granite expects $150 mln revenue from new acquisitions in 2025

* Adjusted EBITDA margin guidance increased to 11.25%-12.25%

* SG&A expenses projected at 9% of revenue, including $40 mln stock-based compensation

Result Drivers

* ACQUISITIONS - Revenue growth driven by acquisition of Dickerson & Bowen, boosting Q2 results

* PROJECT EXECUTION - Improved project execution and favorable claim settlements contributed to increased gross profit

* CAP INCREASE - Record CAP rose $324 mln sequentially, reflecting strong bidding opportunities

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $1.13 $1.16

Revenue bln bln (2

Analysts

)

Q2 Beat $1.93 $1.7 (2

Adjusted Analysts

EPS )

Q2 EPS $1.42

Q2 Beat $86 mln $79.80

Adjusted mln (1

Net Analyst)

Income

Q2 Net $72 mln

Income

Q2 Beat $152 mln $143.20

Adjusted mln (1

EBITDA Analyst)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the construction & engineering peer group is "buy"

* Wall Street's median 12-month price target for Granite Construction Inc ( GVA ) is $108.00, about 13.6% above its August 6 closing price of $93.34

* The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 14 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Why Branded Footwear Retailer Genesco's Shares Are Tumbling Today
Why Branded Footwear Retailer Genesco's Shares Are Tumbling Today
Mar 8, 2024
Genesco Inc shares are plummeting after reporting fourth-quarter FY24 sales growth of 2% year-on-year to $738.95 million, beating the analyst consensus estimate of $705.66 million. Excluding the 14th week, sales would have decreased 2% for the fourth quarter of fiscal 2024. Total comparable sales declined 4%. Overall sales dropped 2% at Journeys, grew 6% at Schuh, up 9% at Johnston & Murphy,...
Novo Nordisk confident of amycretin obesity drug launch this decade
Novo Nordisk confident of amycretin obesity drug launch this decade
Mar 8, 2024
BAGSVAERD, Denmark (Reuters) - Novo Nordisk is very comfortable it will be able to launch the pill version of its experimental weight loss drug amycretin this decade, the drugmaker's head of development told Reuters on Friday, a day after it announced strong early trial data on it. I never commit to timelines but I would be very comfortable to say...
Ani Pharmaceuticals Insider Sold Shares Worth $2,630,864, According to a Recent SEC Filing
Ani Pharmaceuticals Insider Sold Shares Worth $2,630,864, According to a Recent SEC Filing
Mar 8, 2024
08:09 AM EST, 03/08/2024 (MT Newswires) -- Muthusamy Shanmugam, Director, HEAD OF R&D, COO-NOVITIUM OPS, around March 05, 2024, sold 40,000 shares in Ani Pharmaceuticals ( ANIP ) for $2,630,864. Following the Form 4 filing with the SEC, Shanmugam has control over a total of 916,272 shares of the company, with 68,652 shares held directly and 847,620 shares controlled indirectly....
Shockwave Medical Insider Sold Shares Worth $507,294, According to a Recent SEC Filing
Shockwave Medical Insider Sold Shares Worth $507,294, According to a Recent SEC Filing
Mar 8, 2024
08:00 AM EST, 03/08/2024 (MT Newswires) -- Frank T Watkins, Director, on March 06, 2024, sold 2,000 shares in Shockwave Medical ( SWAV ) for $507,294. Following the Form 4 filing with the SEC, Watkins has control over a total of 4,532 shares of the company, with 4,532 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1642545/000164254524000075/xslF345X03/wk-form4_1709864771.xml Price: 261.95, Change: +5.84, Percent Change:...
Copyright 2023-2026 - www.financetom.com All Rights Reserved